Skip to content
2000
Volume 26, Issue 6
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Objective

The anticancer properties of recombinant α-luffin (LUF) are well-established. However, the cytotoxic effects of encapsulating LUF within niosomes on the SKBR3 breast cancer cell line have yet to be explored. Our study aimed to investigate whether this encapsulation strategy could improve cytotoxic effects.

Methods

Alpha-luffin was expressed, purified, and refolded. Then, this protein was utilized to craft an optimal formulation, guided by experimental design. In this work, we have explored various physicochemical properties, including particle size, polydispersity index, zeta potential, morphology, entrapment efficiency, drug release and kinetics, storage stability, and FTIR spectroscopy. Additionally, we have assessed the cellular uptake and cytotoxic effect of the optimized niosome formulation on the SKBR3 breast cancer cell line.

Results

The optimized niosome exhibited a mean diameter of 315±6.4 nm (DLS). Successful encapsulation of LUF into regularly shaped, spherical niosomes was achieved, with an encapsulation efficiency of 73.45±2.4%. Notably, Niosomal LUF (NLUF) exhibited significantly increased cytotoxicity against SKBR3 cells.

Conclusion

These findings suggest that niosomes loaded with LUF hold promise as a potential treatment strategy for breast cancer.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpb/10.2174/0113892010316435240806053230
2024-08-23
2025-09-17

  • From This Site

    /content/journals/cpb/10.2174/0113892010316435240806053230
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. JawarnehS. TalibW.H. Combination of ashwagandha water extract and intermittent fasting as a therapy to overcome cisplatin resistance in breast cancer: An in vitro and in vivo study.Front. Nutr.2022986361910.3389/fnut.2022.86361935859750
     [Google Scholar]
  2. ViegasC. SeckF. FonteP. An insight on lipid nanoparticles for therapeutic proteins delivery.J. Drug Deliv. Sci. Technol.20227710383910.1016/j.jddst.2022.103839
     [Google Scholar]
  3. WilsonT. JohnstonP. LongleyD. Anti-apoptotic mechanisms of drug resistance in cancer.Curr. Cancer Drug Targets20099330731910.2174/15680090978816654719442051
     [Google Scholar]
  4. TemajG. ChichiarelliS. EufemiM. AltieriF. HadziselimovicR. FarooqiA.A. YaylimI. SasoL. Ribosome-directed therapies in cancer.Biomedicines2022109208810.3390/biomedicines1009208836140189
     [Google Scholar]
  5. Laham-KaramN. PintoG.P. PosoA. KokkonenP. Transcription and translation inhibitors in cancer treatment.Front Chem.2020827610.3389/fchem.2020.0027632373584
     [Google Scholar]
  6. BarkhordariF. SohrabiN. DavamiF. MahboudiF. GaroosiY.T. Cloning, expression and characterization of a HER2-alpha luffin fusion protein in Escherichia coli.Prep. Biochem. Biotechnol.201949875976610.1080/10826068.2019.160844731032734
     [Google Scholar]
  7. NarayananS. SurendranathK. BoraN. SuroliaA. KarandeA.A. Ribosome inactivating proteins and apoptosis.FEBS Lett.200557961324133110.1016/j.febslet.2005.01.03815733836
     [Google Scholar]
  8. Abdel-SalamI.M. AshmawyA.M. HilalA.M. EldahshanO.A. AshourM. Chemical composition of aqueous ethanol extract of Luffa cylindrica leaves and its effect on representation of Caspase‐8, Caspase‐3, and the proliferation marker Ki67 in intrinsic molecular subtypes of breast cancer in vitro .Chem. Biodivers.2018158e180004510.1002/cbdv.20180004529874411
     [Google Scholar]
  9. LiuL. WangR. HeW. HeF. HuangG. Cloning and soluble expression of mature alpha-luffin from Luffa cylindrica and its antitumor activities in vitro.Acta Biochim. Biophys. Sin.201042858559210.1093/abbs/gmq05620705600
     [Google Scholar]
  10. AsrorovA.M. GuZ. MinK.A. ShinM.C. HuangY. Advances on tumor-targeting delivery of cytotoxic proteins.ACS Pharmacol. Transl. Sci.20203110711810.1021/acsptsci.9b0008732259092
     [Google Scholar]
  11. PudlarzA. SzemrajJ. Nanoparticles as carriers of proteins, peptides and other therapeutic molecules.Open Life Sci.201813128529810.1515/biol‑2018‑003533817095
     [Google Scholar]
  12. DoT.T. DoT.P. NguyenT.N. NguyenT.C. VuT.T.P. NguyenT.G.A. Nanoliposomal L-asparaginase and its antitumor activities in lewis lung carcinoma tumor-induced BALB/c mice.Adv. Mater. Sci. Eng.201920191810.1155/2019/3534807
     [Google Scholar]
  13. PatelG. PrajapatiB. PathakY. Niosomes in tuberculosis.Tubercular Drug Delivery Systems: Advances in Treatment of Infectious Diseases. ShegokarR. PathakY. ChamSpringer International Publishing202323526010.1007/978‑3‑031‑14100‑3_12
     [Google Scholar]
  14. JadidiA. ShokrgozarM.A. SardariS. MaadaniA.M. Gefitinib-loaded polydopamine-coated hollow mesoporous silica nanoparticle for gastric cancer application.Int. J. Pharm.202262912234210.1016/j.ijpharm.2022.12234236374799
     [Google Scholar]
  15. PurohitS.J. TharmavaramM. RawtaniD. PrajapatiP. PandyaH. DeyA. Niosomes as cutting edge nanocarrier for controlled and targeted delivery of essential oils and biomolecules.J. Drug Deliv. Sci. Technol.20227310343810.1016/j.jddst.2022.103438
     [Google Scholar]
  16. GeX. WeiM. HeS. YuanW.E. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery.Pharmaceutics20191125510.3390/pharmaceutics1102005530700021
     [Google Scholar]
  17. GrijalvoS. PurasG. ZárateJ. Sainz-RamosM. QtaishN.A.L. LópezT. MashalM. AttiaN. Díaz DíazD. PonsR. FernándezE. PedrazJ.L. EritjaR. Cationic niosomes as non-viral vehicles for nucleic acids: Challenges and opportunities in gene delivery.Pharmaceutics20191125010.3390/pharmaceutics1102005030678296
     [Google Scholar]
  18. BaraniM. HajinezhadM.R. ZargariF. ShahrakiS. DavodabadiF. MirinejadS. SargaziS. RahdarA. Díez-PascualA.M. Preparation, characterization, cytotoxicity and pharmacokinetics of niosomes containing gemcitabine: In vitro, in vivo, and simulation studies.J. Drug Deliv. Sci. Technol.20238410450510.1016/j.jddst.2023.104505
     [Google Scholar]
  19. Delf LoveymiB. JelvehgariM. Zakeri-MilaniP. ValizadehH. Statistical optimization of oral vancomycin-eudragit rs nanoparticles using response surface methodology.Iran. J. Pharm. Res.20121141001101224250531
     [Google Scholar]
  20. LandiF.S. NegahdariB. EsmaeiliF. KolivandS. AmaniA. Introducing electrospray as a potent technique to deliver chitosan/pDNA nanoparticles to eukaryotic cells.J. Nano Res.202166738410.4028/www.scientific.net/JNanoR.66.73
     [Google Scholar]
  21. BarkhordariF. RaiganiM. Talebkhan GaroosiY. MahboudiF. DavamiF. Optimization of enbase fed-batch cultivation to improve soluble fraction ratio of α-luffin ribosome inactivating protein.Iran. J. Biotechnol.2018161495910.21859/ijb.148230555837
     [Google Scholar]
  22. TsumotoK. UmetsuM. KumagaiI. EjimaD. PhiloJ.S. ArakawaT. Role of arginine in protein refolding, solubilization, and purification.Biotechnol. Prog.20042051301130810.1021/bp049879315458311
     [Google Scholar]
  23. SadeghiS. BakhshandehH. Ahangari CohanR. PeiroviA. EhsaniP. NorouzianD. Synergistic anti-staphylococcal activity of niosomal recombinant lysostaphin-LL-37.Int. J. Nanomedicine2019149777979210.2147/IJN.S23026931849468
     [Google Scholar]
  24. Yadavar-NikraveshM.S. AhmadiS. MilaniA. AkbarzadehI. KhoobiM. VahabpourR. BolhassaniA. BakhshandehH. Construction and characterization of a novel Tenofovir-loaded PEGylated niosome conjugated with TAT peptide for evaluation of its cytotoxicity and anti-HIV effects.Adv. Powder Technol.20213293161317310.1016/j.apt.2021.05.047
     [Google Scholar]
  25. Ur RehmanM. RasulA. KhanM.I. HanifM. AamirM.N. WaqasM.K. HameedM. AkramM.R. Development of niosomal formulations loaded with cyclosporine A and evaluation of its compatibility.Trop. J. Pharm. Res.20181781457146410.4314/tjpr.v17i8.1
     [Google Scholar]
  26. JadidM.F.S. Jafari-GharabaghlouD. BahramiM.K. BonabiE. ZarghamiN. Enhanced anti-cancer effect of curcumin loaded-niosomal nanoparticles in combination with heat-killed Saccharomyces cerevisiae against human colon cancer cells.J. Drug Deliv. Sci. Technol.20238010416710.1016/j.jddst.2023.104167
     [Google Scholar]
  27. ThabetY. ElsabahyM. EissaN.G. Methods for preparation of niosomes: A focus on thin-film hydration method.Methods202219991510.1016/j.ymeth.2021.05.00434000392
     [Google Scholar]
  28. MoammeriA. AbbaspourK. ZafarianA. JamshidifarE. MotasadizadehH. Dabbagh MoghaddamF. SalehiZ. MakvandiP. DinarvandR. pH-responsive, adorned nanoniosomes for codelivery of cisplatin and epirubicin: synergistic treatment of breast cancer.ACS Appl. Bio Mater.20225267569010.1021/acsabm.1c0110735129960
     [Google Scholar]
  29. AparajayP. DevA. Functionalized niosomes as a smart delivery device in cancer and fungal infection.Eur. J. Pharm. Sci.202216810605210.1016/j.ejps.2021.10605234740786
     [Google Scholar]
  30. BarretR. 3 - Importance and evaluation of lipophilicity.Therapeutical Chemistry. BarretR. Elsevier2018537810.1016/B978‑1‑78548‑288‑5.50003‑2
     [Google Scholar]
  31. NingM. GuoY. PanH. ZongS. GuZ. Preparation and characterization of EP-liposomes and Span 40-niosomes.Pharmazie200661320821216599261
     [Google Scholar]
  32. AhmadiS. SerajM. ChianiM. HosseiniS. BazzazanS. AkbarzadehI. SaffarS. MostafaviE. In vitro development of controlled-release nanoniosomes for improved delivery and anticancer activity of letrozole for breast cancer treatment.Int. J. Nanomedicine2022176233625510.2147/IJN.S38408536531115
     [Google Scholar]
  33. NowrooziF. AlmasiA. JavidiJ. HaeriA. DadashzadehS. Effect of surfactant type, cholesterol content and various downsizing methods on the particle size of niosomes.Iran. J. Pharm. Res.201817Suppl. 211131011337
     [Google Scholar]
  34. AkbarzadehI. Tavakkoli YarakiM. BourbourM. NoorbazarganH. LajevardiA. Sadat ShilsarS.M. HeidariF. MousavianS.M. Optimized doxycycline-loaded niosomal formulation for treatment of infection-associated prostate cancer: An in-vitro investigation.J. Drug Deliv. Sci. Technol.20205710171510.1016/j.jddst.2020.101715
     [Google Scholar]
  35. RezaeiN. Kazem ArkiM. Miri-LavasaniZ. SolhiR. KhoramipourM. RashediH. Asadzadeh AghdaeiH. Hossein-KhannazerN. MostafaviE. VosoughM. Co-delivery of doxorubicin and paclitaxel via noisome nanocarriers attenuates cancerous phenotypes in gastric cancer cells.Eur. J. Pharm. Biopharm.2023188334710.1016/j.ejpb.2023.04.01637105361
     [Google Scholar]
  36. IbrahimT.M. Exploitation of transdermal nanobilosomal gel platforms for ameliorating anti-diabetic activity of empagliflozin following I-optimal design.J. Drug Deliv. Sci. Technol.20238410445510.1016/j.jddst.2023.104455
     [Google Scholar]
  37. AttiaD El-NabarawiM TeaimaM. Preparation and evaluation of niosomes containing an anti- cellulite drug.2015
     [Google Scholar]
  38. WitikaB.A. BasseyK.E. DemanaP.H. Siwe-NoundouX. PokaM.S. Current advances in specialised niosomal drug delivery: Manufacture, characterization and drug delivery applications.Int. J. Mol. Sci.20222317966810.3390/ijms2317966836077066
     [Google Scholar]
  39. Antonio Villaverde Nanoparticles in translational science and medicine.LondonElsevier Academic Press2011
     [Google Scholar]
  40. ZengL. AnL. WuX. Modeling drug-carrier interaction in the drug release from nanocarriers.J. Drug Deliv.2011201111510.1155/2011/37030821845225
     [Google Scholar]
  41. MaheraniB. Arab-TehranyE. KheirolomoomA. GenyD. LinderM. Calcein release behavior from liposomal bilayer; Influence of physicochemical/mechanical/structural properties of lipids.Biochimie201395112018203310.1016/j.biochi.2013.07.00623871914
     [Google Scholar]
  42. MogheriF. JokarE. AfshinR. AkbariA.A. DadashpourM. Firouzi-amandiA. Serati-NouriH. ZarghamiN. Co-delivery of metformin and silibinin in dual-drug loaded nanoparticles synergistically improves chemotherapy in human non-small cell lung cancer A549 cells.J. Drug Deliv. Sci. Technol.20216610275210.1016/j.jddst.2021.102752
     [Google Scholar]
  43. PatelG.K. PrajapatiB. PathakY. Niosomes in malaria.Malarial Drug Delivery Systems: Advances in Treatment of Infectious Diseases. ShegokarR. PathakY. ChamSpringer International Publishing202325327710.1007/978‑3‑031‑15848‑3_12
     [Google Scholar]
  44. HonarvariB. KarimifardS. AkhtariN. MehraryaM. MoghaddamZ.S. AnsariM.J. Folate-targeted curcumin-loaded niosomes for site-specific delivery in breast cancer treatment: in silico and in vitro study.Molecules20222710.3390/molecules27144634
     [Google Scholar]
  45. LiD. MartiniN. WuZ. ChenS. FalconerJ.R. LockeM. ZhangZ. WenJ. Niosomal nanocarriers for enhanced dermal delivery of epigallocatechin gallate for protection against oxidative stress of the skin.Pharmaceutics202214472610.3390/pharmaceutics1404072635456560
     [Google Scholar]
  46. ZhangY. ZhangK. WuZ. GuoT. YeB. LuM. ZhaoJ. ZhuC. FengN. Evaluation of transdermal salidroside delivery using niosomes via in vitro cellular uptake.Int. J. Pharm.2015478113814610.1016/j.ijpharm.2014.11.01825448576
     [Google Scholar]
  47. AgarwalS. MohamedM.S. RaveendranS. RochaniA.K. MaekawaT. KumarD.S. Formulation, characterization and evaluation of morusin loaded niosomes for potentiation of anticancer therapy.RSC Advances2018857326213263610.1039/C8RA06362A35547672
     [Google Scholar]
  48. El-FarS.W. Abo El-EninH.A. AbdouE.M. NafeaO.E. AbdelmonemR. Targeting colorectal cancer cells with niosomes systems loaded with two anticancer drugs models; Comparative in vitro and anticancer studies.Pharmaceuticals202215781610.3390/ph1507081635890115
     [Google Scholar]
  49. MoghaddamF.D. AkbarzadehI. MarzbankiaE. FaridM. KhalediL. ReihaniA.H. Delivery of melittin-loaded niosomes for breast cancer treatment: an in vitro and in vivo evaluation of anti-cancer effect.Cancer Nano2021121410.21203/rs.3.rs‑136057/v1
     [Google Scholar]
  50. AhmadiS. AkbarzadehI. ChianiM. SerajM. NoorbazarganH. SaffarS. An optimized and well-characterized niosome-based nanocarrier for letrozole: A brand- new hybrid therapy for breast cancer.Research Square202110.21203/rs.3.rs‑1197164/v1
     [Google Scholar]
/content/journals/cpb/10.2174/0113892010316435240806053230
Loading
Formulation, Characterization, and Potential Therapeutic Implications of Encapsulated Recombinant Alpha-luffin in Niosomes
Current Pharmaceutical Biotechnology 26, 923 (2025); https://doi.org/10.2174/0113892010316435240806053230
/content/journals/cpb/10.2174/0113892010316435240806053230
/content/journals/cpb/10.2174/0113892010316435240806053230
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): alpha-luffin; drug delivery; Niosome; recombinant protein; response surface methodology; ribosome-inactivating protein

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test